OMERS ADMINISTRATION Corp Sells 733 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

OMERS ADMINISTRATION Corp cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,183 shares of the biopharmaceutical company’s stock after selling 733 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Gilead Sciences were worth $6,390,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Norges Bank bought a new stake in shares of Gilead Sciences during the fourth quarter worth $1,789,254,000. FMR LLC grew its holdings in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock worth $3,724,306,000 after acquiring an additional 7,157,113 shares during the last quarter. Pacer Advisors Inc. grew its holdings in Gilead Sciences by 723.3% during the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock worth $594,370,000 after acquiring an additional 5,653,075 shares during the last quarter. Northern Trust Corp grew its holdings in Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock worth $1,377,707,000 after acquiring an additional 2,458,954 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $207,340,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Down 2.3%

Gilead Sciences stock opened at $101.43 on Wednesday. The firm has a 50-day moving average of $106.71 and a 200-day moving average of $99.51. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a market cap of $126.30 billion, a price-to-earnings ratio of 274.14, a P/E/G ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.32) earnings per share. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 3.12%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s dividend payout ratio is currently 66.53%.

Wall Street Analyst Weigh In

GILD has been the topic of several research analyst reports. Bank of America increased their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. BMO Capital Markets increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Wells Fargo & Company raised their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Piper Sandler raised their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Finally, Morgan Stanley raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $110.55.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares of the company’s stock, valued at $19,977,938.37. This trade represents a 9.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 22,929 shares of company stock worth $2,644,895 over the last quarter. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.